Kuur is a Texas-based biopharmaceutical company that researches and develops CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies... Read more
Kuur is a Texas-based biopharmaceutical company that researches and develops CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies... Read more
News
Aug 30, 2021
Seeking Alpha
Kuur Therapeutics: New CEO at Ziopharm Oncology, shares up 3%
May 05, 2021
The Business Journals: Houston
Kuur Therapeutics: Athenex acquires Houston biotech co. Kuur Therapeutics for $185M
May 04, 2021
BioSpace
Kuur Therapeutics: Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
Jan 21, 2021
MarketScreener
Kuur Therapeutics: IP : Kuur Therapeutics Ltd - Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform
Oct 12, 2020
MarketScreener
Kuur Therapeutics: Kuur Therapeutics : Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine
Sep 30, 2020
MarketScreener
Kuur Therapeutics: IP : Kuur Therapeutics Ltd - Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy
Mar 12, 2020
Medical Buyer
Kuur Therapeutics: Cell Medica Rebrands As Kuur Therapeutics With New CEO
Mar 12, 2020
PharmaLive
Kuur Therapeutics: CELL MEDICA REBRANDS AS KUUR THERAPEUTICS WITH NEW CEO
Mar 10, 2020
FIRSTWORD PHARMA
Kuur Therapeutics: Kuur Therapeutics Launches to Develop and Commercialize "Off-the-shelf" CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors
May 01, 2019
BioPortfolio
Kuur Therapeutics: Cell Medica Collaborators Baylor College of Medicine and Texas Childrens Hospital Present Preclinical Data for an offtheshelf CARNKT Therapy Platform at American Society of Gene & Cell Therapy 22nd Annual Meeting
